Evotec Stock Forecast, Price & News

Evotec (OTCMKTS:EVTCY) Frequently Asked Questions

Is Evotec a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Evotec stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVTCY, but not buy additional shares or sell existing shares.
View analyst ratings for Evotec or view top-rated stocks.

What stocks does MarketBeat like better than Evotec?

Wall Street analysts have given Evotec a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evotec wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Evotec?

Evotec saw a decrease in short interest in August. As of August 31st, there was short interest totaling 100 shares, a decrease of 75.0% from the August 15th total of 400 shares. Based on an average daily trading volume, of 600 shares, the short-interest ratio is presently 0.2 days.
View Evotec's Short Interest.

When is Evotec's next earnings date?

Evotec is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Evotec.

How has Evotec's stock been impacted by COVID-19?

Evotec's stock was trading at $49.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EVTCY stock has increased by 113.8% and is now trading at $104.96.
View which stocks have been most impacted by COVID-19.

Who are Evotec's key executives?

Evotec's management team includes the following people:

• Werner Lanthaler, Chief Executive Officer
• Craig L. Johnstone, Chief Operating Officer & Member-Management Board
• Enno Spillner, Chief Financial Officer
• Cord E. Dohrmann, Chief Scientific Officer
• Volker Braun, SVP, Head-Investor Relations & ESG

Who are some of Evotec's key competitors?

Some companies that are related to Evotec include Astellas Pharma (ALPMY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Genmab A/S (GNMSF), Genmab A/S (GMAB), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), Viatris (VTRS), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN) and Maravai LifeSciences (MRVI).
View all of EVTCY's competitors.

What is Evotec's stock symbol?

Evotec trades on the OTCMKTS under the ticker symbol "EVTCY."

How do I buy shares of Evotec?

Shares of EVTCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evotec's stock price today?

One share of EVTCY stock can currently be purchased for approximately $104.96.

How much money does Evotec make?

Evotec has a market capitalization of $8.66 billion and generates $572.16 million in revenue each year.

How many employees does Evotec have?

Evotec employs 3,572 workers across the globe.

What is Evotec's official website?

The official website for Evotec is www.evotec.com.

Where are Evotec's headquarters?

Evotec is headquartered at Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419.

How can I contact Evotec?

Evotec's mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The company can be reached via phone at (494) 056-0810 or via email at [email protected].